Vivos Therapeutics Inc(VVOS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.07 | Insider Own | 18.91% | Shs Outstand | 33.6M | Perf Week | 2.13% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 85.37% | Insider Trans | - | Shs Float | 27.3M | Perf Month | -17.54% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.21 | Inst Own | 1.58% | Short Float | 5.97% | Perf Quarter | -67.98% |
| Income | -0.03B | P/S | 0.25 | EPS this Y | 50.48% | Inst Trans | -4.92% | Short Ratio | 0.13 | Perf Half Y | -87.6% |
| Sales | 0.02B | P/B | - | EPS next 5Y | - | ROA | -101.47% | Short Interest | 1.63M | Perf YTD | -92.43% |
| Book/sh | -0.34 | P/C | 2.92 | EPS past 3/5Y | 56.99% 39.15% | ROE | -6629.43% | 52W High | -95.51% ($3.42) | Perf Year | -95.27% |
| Cash/sh | 0.05 | P/FCF | - | Sales past 3/5Y | 2.87% 5.95% | ROIC | -35356.94% | 52W Low | 19.24% ($0.13) | Perf 3Y | -97.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -10.29% | Gross Margin | 53.33% | Volatility(W/M) | 6.47% 8.8% | Perf 5Y | -99.84% |
| Dividend TTM | - | EV/Sales | 0.81 | Sales Y/Y TTM | 45.21% | Oper. Margin | -107.92% | ATR (14) | 0.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.21 | EPS Q/Q | 43.8% | Profit Margin | -121.8% | RSI (14) | 36.63 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.21 | Sales Q/Q | 34.9% | SMA20 | -3.01% ($0.15) | Beta | 6.31 | Target Price | $0.75 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/14 | SMA50 | -36.28% ($0.24) | Rel Volume | 0.05 | Prev Close | $0.15 |
| Employees | 268 | LT Debt/Eq | - | EPS/Sales Surpr. | 24.39% -8.53% | SMA200 | -83.34% ($0.9) | Avg Volume(3M) | 12.34M | Price | $0.15 |
| IPO | 2020/12/11 | Option/Short | No/Yes | Trades | 494 | Volume | 573,014 | Change | -0.26% |
Vivos Therapeutics ( is a medical device company that develops and commercializes oral appliances for the non-surgical treatment of obstructive sleep apnea (OSA) and snoring. Its flagship offerings include the FDA 510(k)-cleared CARE (Complete Airway Repositioning and/or Expansion) oral appliance line, along with a portfolio such as VidaSleep™ and DNA that addresses different age groups and severity levels, covering adult severe OSA, pediatric OSA, and mild-to-moderate OSA and snoring.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual That is 5% of its average volume.
VVOS has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +50.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $25. Peers typically go for $155.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +79% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #129 of 143 in the industry
Based on market cap of $5M.
FAQ
What kind of company is VVOS?
VVOS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of VVOS?
The market cap of VVOS is approximately $5M, ranking 5,668 within its sector.
What is the 52-week high and low for VVOS?
VVOS has recorded a 52-week high of $3.42 and a low of $0.13.
